Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 1 of the 24 sources its claims cite were checked for support.
Abstract
Epigenetic modifiers have fundamental roles in defining unique cellular identity through the establishment and maintenance of lineage-specific chromatin and methylation status. Several DNA modifications such as 5-hydroxymethylcytosine (5hmC) are catalysed by the ten eleven translocation (Tet) methylcytosine dioxygenase family members, and the roles of Tet proteins in regulating chromatin architecture and gene transcription independently of DNA methylation have been gradually uncovered. However, the regulation of immunity and inflammation by Tet proteins independent of their role in modulating DNA methylation remains largely unknown. Here we show that Tet2 selectively mediates active repression of interleukin-6 (IL-6) transcription during inflammation resolution in innate myeloid cells, including dendritic cells and macrophages. Loss of Tet2 resulted in the upregulation of several inflammatory mediators, including IL-6, at late phase during the response to lipopolysaccharide challenge. Tet2-deficient mice were more susceptible to endotoxin shock and dextran-sulfate-sodium-induced colitis, displaying a more severe inflammatory phenotype and increased IL-6 production compared to wild-type mice. IκBζ, an IL-6-specific transcription factor, mediated specific targeting of Tet2 to the Il6 promoter, further indicating opposite regulatory roles of IκBζ at initial and resolution phases of inflammation. For the repression mechanism, independent of DNA methylation and hydroxymethylation, Tet2 recruited Hdac2 and repressed transcription of Il6 via histone deacetylation. We provide mechanistic evidence for the gene-specific transcription repression activity of Tet2 via histone deacetylation and for the prevention of constant transcription activation at the chromatin level for resolving inflammation.
Overview
CoChat Summary
TL;DR
Tet2 actively represses Il6 transcription during the late phase of LPS-driven inflammation in myeloid cells by recruiting Hdac2 to the Il6 promoter, independent of DNA methylation. Tet2 loss prolongs IL-6 production and worsens endotoxin shock and DSS-induced colitis in mice.
Key findings
- In Tet2-deficient or Tet2-silenced dendritic cells and macrophages, the early LPS-induced rise in Il6 mRNA before 4 h was largely unchanged, but after 8 h Il6 mRNA remained elevated while control cells declined; IL-6 protein also increased, whereas Tnfa levels were similar. Tet3 silencing barely affected Il6.
- Tet2-deficient mice produced more IL-6 after systemic LPS, especially late, and showed worse lung tissue damage; in DSS colitis they had greater weight loss, higher IL-6, more inflammatory cell infiltration, and mucosal disruption. In Tet2-deficient BMDC, 22 genes were downregulated and 13 upregulated; 12 of the upregulated genes were TLR-induced, including Il6.
- IκBζ interacted with Tet2 and was required for Tet2 binding to the Il6 promoter at late LPS phase. IκBζ overexpression increased Il6 early but reduced it late, and Tet2 loss impaired this late repression.
- Tet2 associated with Hdac1/Hdac2 through its core-DSBH domain. Hdac2 binding at the Il6 promoter fell early and returned late; Hdac2 knockdown increased Il6 transcription and histone acetylation at 10 h, with Hdac1 compensation by 12 h. Catalytically mutant Tet2 still repressed Il6, and Tet2 loss reduced Hdac2 binding and late histone deacetylation.
Methods
- Mouse models included C57BL/6, Tet2fl/fl, Tet2-deficient, and Lyz2-Cre myeloid-specific Tet2-deficient mice; human monocytes came from healthy donors. Cells studied included BMDC, BMM, peritoneal macrophages, and splenic T, B, and NK cells, with LPS at 100 ng/ml; in vivo models were endotoxin shock and DSS colitis.
- Assays included RNA-seq, qPCR, ELISA, immunoblot, immunoprecipitation, co-IP with LC-MS/MS, ChIP and re-ChIP, luciferase reporters, siRNA knockdown, overexpression, and a GAL4-based recruitment assay.
- Statistics used unpaired Student’s t-tests with *P < 0.05 and P < 0.01; error bars were s.e.m. or s.d.; data were from triplicate technical or biological replicates and representative of three independent experiments.
Limitations
- The paper states that animal studies did not randomize by weight or sex and did not use blinding, and that sample size was not predetermined by a statistical method. It also states that HEK293T cells were not authenticated or tested for mycoplasma.
- Evident from the text: Hdac2 knockdown effects were transient because Hdac1 appeared to compensate by 12 h, complicating conclusions about Hdac2-specific repression.
- Evident from the text: many mechanistic experiments relied on overexpression or siRNA in HEK293T or primary cells, and the in vivo work used two inflammatory models; the authors note that additional Tet2-repressed mediators may exist in tissue-resident immune cells.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
1 Valid · 0 Not valid · 16 Not checked · 86 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“MS-275 strongly inhibits Hdac1/2 over Hdac3 (ref. 19)”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
What the sources say
- Supportedcites [19] Inoue S Mai A Dyer MJ Cohen GM Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2006 66 6785 6792 16818655 source
In the Results section 'Expression of HDACs in CLL cells and various cell lines', our copy reports that MS-275 (1-2.5 micromol/L) inhibited HDAC1 and HDAC2 activities by ~50-70% whereas 1 micromol/L did not inhibit HDAC3 (~20% only at 2.5 micromol/L), and explicitly frames the experiment as confirming that 'MS-275 was selectively inhibiting HDAC1 and HDAC2 rather than HDAC3'. The same section also states MS-275 preferentially inhibits HDAC1 (IC50 ~0.3 micromol/L) versus HDAC3 (IC50 ~8 micromol/L), though that IC50 comparison is itself credited to ref. 32; the paper's own immunoprecipitation/activity data carry the claim. Thus the paraphrase 'strongly inhibits Hdac1/2 over Hdac3' matches what this source attributes to MS-275. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“overexpressed Tet2 recruited more endogenous Hdac2 to the Il6 promoter”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Attenuated histone deacetylation in Tet2-deficient cells was also observed at late phase during LPS response”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“loss of Tet2 caused higher expression of IFN-γ in activated CD8+ T cells”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Loss of Tet2 barely affects TLR4 signalling pathways”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Extended Data
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
45 more claims
Create a free account to see all 103 claims and to verify the 15 references still open.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 28
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“mice deficient in Tet2 developed more severe inflammation in several tissues upon challenge with bacterial endotoxin”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [91]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“this effect on Il6 expression was independent of the catalytic function of Tet2”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [91]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss of TET2, an enzyme that catalyzes DNA demethylation, results in prolonged and high expression of proinflammatory cytokines, including IL-6 [180].”
From Transition from inflammation to proliferation: a critical step during wound healing (2016) · cites this paper as [180]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As CHIP-associated mutations are known to alter the development and function of myeloid cells”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results contrast with findings in peripheral macrophages after intraperitoneal injection in vivo (Zhang et al., 2015).”
From TET2 Regulates the Neuroinflammatory Response in Microglia (2019) · cites this paper as Zhang et al., 2015
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Ito, S., D’Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,373
TET enzymes, TDG and the dynamics of DNA demethylation
Kohli, R. M., & Zhang, Y. (2013) · Nature · doi:10.1038/nature12750 · Cited by 1,623
Suppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Gene-specific control of inflammation by TLR-induced chromatin modifications
Foster, S. L., Hargreaves, D. C., & Medzhitov, R. (2007) · Nature · doi:10.1038/nature05836 · Cited by 1,344
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Self-citationImpaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Ko, M., Huang, Y., Jankowska, A. M., Pape, U. J., Tahiliani, M., Bandukwala, H. S., An, J., Lamperti, E. D., Koh, K. P., Ganetzky, R., et al. (2010) · Nature · doi:10.1038/nature09586 · Cited by 1,213
Distinct Effects of T-bet in T H 1 Lineage Commitment and IFN-γ Production in CD4 and CD8 T Cells
Szabo, S. J., Sullivan, B. M., Stemmann, C., Satoskar, A. R., Sleckman, B. P., & Glimcher, L. H. (2002) · Science · doi:10.1126/science.1065543 · Cited by 1,172
Cited by
Items 701–797 of 797
Páramo, J. A. (2018) · Medicina Clínica · doi:10.1016/j.medcli.2018.04.007
Páramo, J. A. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.07.006
Cunha, N., Hernández-Aragüés, I., Fattouh, K., Frings, V. G., Stembridge, N. S., & Kuonen, F. (2018) · European Journal of Dermatology · doi:10.1684/ejd.2018.3384
Role of histone acetylation and DNA methylation in hepatic inflammatory response
Wang, Y., & Gong, Z. (2019) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v27.i17.1050
DiNardo, A. R., & Mandalakas, A. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-25381-3_10
[Focus on the 14th International Symposium on Dendritic Cells].
Shen, L., & Wang, Q. (2017) · PubMed Central · doi:10.3785/j.issn.1008-9292.2017.02.16
Dutta, A., Datta, S., & Snehlata, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85652-2.00011-7
Franco, O. A., & Morales, N. O. (2021) · Revista Colombiana de Cancerología · doi:10.35509/01239015.726
Cheng, T., Zhou, C., Pang, J., Tretyakova, N. Y., Tse, W. W., Liu, Y., & Liu, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1432174/v1
Self-citationLee, M., Li, J., Fang, S., Zhang, J., Vo, A. T. T., Han, W., Zeng, H., Isgandarova, S., Martinez-Moczygemba, M., Han, W., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-55173/v1
“Tet2-deficient hematopoietic stem cells, lymphoid or 54 myeloid cells exhibited aberrant immune activities when responding to external stimulations (18-20).”
BackgroundFaculty Opinions recommendation of The loss of TET2 promotes CD8+ T cell memory differentiation.
Pipkin, M. E. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732129854.793562847
TSE, C. (2022) · Cronfa (Swansea University) · doi:10.23889/suthesis.60060
Ismail, W. M., Fernandez, J. A., Binder, M., Lasho, T. L., Kim, M., Geyer, S. M., Mazzone, A., Finke, C. M., Mangaonkar, A. A., Lee, J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.25.505316
Giai, V., Bensi, T., Bertassello, C., Savio, M., Ferrero, D., Ciriello, M. M., & Ladetto, M. (2022) · Journal of Biotechnology and Biomedicine · doi:10.26502/jbb.2642-91280063
“It is important to underline that many recurrent mutations in MDS are involved in the regulation of oxidative status in MDS microenvironment: for example, TET2 recruited histone deacetylase enzyme 2 (HDAc2) and repressed transcription of interleukin-6 (IL-6), one of the most important inflammation cytokines that promo…”
BackgroundImmunotherapy for Primary Cancers of Central Nervous System
Maroufi, S. F., Mohammadi, E., Namvar, M., Iranmehr, A., Rezaei, N., & Hanaei, S. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_240-1
Data from Tet2 Inactivation Enhances the Antitumor Activity of Tumor-Infiltrating Lymphocytes
Lee, M., Li, J., Li, J., Fang, S., Zhang, J., Vo, A. T. T., Han, W., Zeng, H., Isgandarova, S., Martinez-Moczygemba, M., et al. (2023) · doi:10.1158/0008-5472.c.6513645.v1
Wang, D., Yang, S., Zeng, Y., Tang, Z., Liu, Y., Li, X., & Zong, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2709268/v1
Self-citationCaiati, C., & Jirillo, E. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230503094723 · Cited by 2
Wang, Y. (2023) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.74343
Neuendorff, N. R., Bittner, A., Flossdorf, S., Mauer, T., Schmitz, F., Neuhoff, N. V., Köster, J., Mölder, F., Schneider, M., Turki, A. T., et al. (2023) · Ageing and Cancer Research & Treatment · doi:10.37155/2972-4759-2023-01-01-4 · Cited by 1
“Most of the mutations confer to a pro-inflammatory phenotype, which is based on pre-clinical [18-20] and clinical data [10, .”
BackgroundThe Origin of Clonal Hematopoiesis and Its Implication in Human Diseases
Zhang, Z., & Sun, J. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-7471-9_5 · Cited by 1
Tet2-mediated macrophage activation promotes liver regeneration
Chen, Y., Meng, L., Xu, N., Chen, H., Wei, X., Lu, D., Wang, S., & Xu, X. (2023) · Korean Journal of Transplantation · doi:10.4285/atw2023.f-8988
Clonal hematopoiesis and COVID‐19 hospitalization in Danish adults
Sequeros, C. B., Tulstrup, M., Bliddal, S., Sørensen, K. M., Nissen, J., Rezahosseini, O., Brooks, P. T., Feenstra, B., Gang, A. O., Geller, F., et al. (2024) · HemaSphere · doi:10.1002/hem3.58
Ismail, W. M., Fernandez, J. A., Binder, M., Lasho, T., Kim, M., Geyer, S. M., Mazzone, A., Finke, C. M., Mangaonkar, A. A., Lee, J., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4481664/v1
Impact of TET2 Mutations on Haematopoietic Stem Cell Resilience to Immune-Related Stress
Encabo, H. H., D’Agostino, G. A., Ferrelli, A., Sharma, A., Mian, S., Albornoz, M. G., Ariza‐McNaughton, L., & Bonnet, D. A. (2024) · EMJ Hematology · doi:10.33590/emjhematol/wjnj7334
Metabolic changes and functional activity of macrophages in homeostasis and in inflammation (review)
Yurakova, T. R., Gorshkova, E. A., Nosenko, M. A., & Drutskaya, M. S. (2024) · Biochemistry (Moscow) · doi:10.31857/s0320972524050047
The diagnostic value of IL-6 and thymidine phosphorylase in the progression of osteosarcoma
Azeez, B. A. B., Alhussain, G. S. A., Salman, R. S., & Al-Fahham, A. A. (2025) · Genij Ortopedii · doi:10.18019/1028-4427-2025-31-2-245-251
Wu, Y., Dai, T., Qin, J., Guo, J., Fan, J., Mei, J., Li, X., & Liu, F. (2025) · Biocell · doi:10.32604/biocell.2025.061289
“Furthermore, HDAC2 modulates inflammation by directly interacting with the IL-6 promoter region in DCs, leading to the suppression of IL-6 expression [41].”
Self-citationFeng, G., Zhang, Y., Wu, H., Zhu, L., Xu, H., Ma, Z., & Huang, Y. J. (2025) · Digital Chinese Medicine · doi:10.1016/j.dcmed.2025.03.009
Boyle, J. J., Chiappo, D., Cooper, S. M., Tapeng, L., Sinha, S., Walter, E. R. H., Lai, T., & Long, N. J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119786
Jarabek, A., Davis, X. D., Oliver, M., Wang, Y., Chen, H., Bohannon, J. K., & Zinkel, S. S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.08.674943
“11,12 Additionally, RIPK1 is essential for inflammatory signaling.”
Alsugair, A. K. A., & Mangaonkar, A. A. (2025) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-025-00757-y
“…of inflammation as a consequence of mutant HSCs. TET2 -mutant HSCs have been reported to results in enhanced IL-6 signaling, since TET2 enzyme is involved in selective repression of IL-6 during inflammation resolution within innate myeloid cells such as dendritic cells and macrophages [ 17 ].”
Immunotherapy for Primary Cancers of Central Nervous System
Maroufi, S. F., Mohammadi, E., Namvar, M., Iranmehr, A., Rezaei, N., & Hanaei, S. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_240
The Role of Inflammation in CMML Pathobiology and Progression
Neupane, N., & Padron, E. (2025) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-025-00756-z · Cited by 1
“This mechanism has been mechanistically demonstrated in murine and human myeloid cells, establishing a direct molecular link between clonal hematopoiesis and dysregulated inflammatory cytokine production [ 27, 45].”
Elvira‐Matelot, E., Stolz, A., Cheng, X. U. A. N., Freitas, C., Chelbi, R., Ait-Ougouram, H., Fandrei, D., Ye, M., Nelson, E., Maillard, C., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7934135/v1
Pantazis, J. C., & Palmer, A. C. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0941
Cheng, T., Zhou, C., Bian, S., Sobeck, K., & Liu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26697467
Self-citationSwaminathan, A. C., Barfield, R., Zhang, M., Povysil, G., Chen, C., Frankel, C. W., Kelly, F. L., McKinney, M., Todd, J. L., Allen, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24465055
Jiang, X., Gao, J., Fei, X., Geng, Y., Yue, X., Shi, Z., Cheng, X., Zhao, T., Fan, M., Wu, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26378038
Shi, Y., Li, B., Huang, X., Kou, W., Zhai, M., Zeng, Y., You, S., Yu, Q., Zhao, Y., Zhuang, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22615310
Chen, Y., Meng, L., Xu, N., Chen, H., Wei, X., Lu, D., Wang, S., & Xu, X. (2024) · Figshare · doi:10.6084/m9.figshare.25138050
Shi, Y., Li, B., Huang, X., Kou, W., Zhai, M., Zeng, Y., You, S., Yu, Q., Zhao, Y., Zhuang, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22615307
Chen, Y., Meng, L., Xu, N., Chen, H., Wei, X., Lu, D., Wang, S., & Xu, X. (2024) · Figshare · doi:10.6084/m9.figshare.25137935
The Epigenetic Regulation of Exerkines
Hou, Y., Wang, S., Jia, Y., & Zhao, H. (2025) · Epigenetics and human health · doi:10.1007/978-3-032-08045-5_13
Tet2 modulates ER stress responses related to β-cell death and autoimmunity in diabetes
Rui, J., Kothari, M., Kursawe, R., Barkestani, M. N., Genosar, R., Clark, P. L., Stitzel, M. L., & Herold, K. C. (2026) · iScience · doi:10.1016/j.isci.2026.114818
“21 The role of Tet2 in resistance to immune killing prompted us to test the effects of Tet2 deletion in progression to diabetes in NOD mice.”
Boosani, A., & Green, J. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.04.703872
“Knock down of TET1 in THP-1 cells was shown to reduce the expression of TNF- even in presence of the inflammation inducer, LPS 13 .”
InfluentialJiang, W., Yu, P., Liang, G.-H., Tian, W.-B., Li, Y.-F., Cai, M.-T., Zhang, L.-X., Yang, Y., & Dong, M. (2026) · The Journal of Headache and Pain · doi:10.1186/s10194-026-02296-0
“Previous studies have shown that transcription factors can recruit TET enzymes to specific genomic loci to modulate local DNA methylation, including IκBζ-mediated targeting of TET2 to cytokine promoters and PPARγ-dependent recruitment of TET1 [40].”
Tran, V. L., Johnson, K. D., & Bresnick, E. H. (2026) · Experimental Hematology · doi:10.1016/j.exphem.2026.105405
TET1 deficiency amplifies macrophage inflammatory signaling associated with Crohn’s disease
Perez, R., Paul, R., Kumar, P., Tutkun, A., Webb, D., McGorty, S., Wieckowski, T., Yap, Y. S., Leesang, T. E., Vlantis, P. I., et al. (2026) · Inflammation Research · doi:10.1007/s00011-026-02228-3
Mahé, E. A. (2016) · theses.fr (ABES) · doi:10.70675/daf5feb1z2f61z4e8bzb3a6za907fab675b8
Etude du rôle et des modes d’action de l’enzyme épigénétique TET chez la drosophile
Boulet, M. (2021) · theses.fr (ABES) · doi:10.70675/0c0f818fz10b0z42d5zbea1zde77534d9ffa
Osmani, N. E. (2022) · theses.fr (ABES) · doi:10.70675/44703178z2ad1z4ebcza891z61cf9febffe8 · Cited by 1
Etude de l'hétérogénéité du microenvironnement et des cellules tumorales dans le lymphome TFH
Mboumba, D. L. (2024) · theses.fr (ABES) · doi:10.70675/ab609d7azbd90z40daza2b9za9670f82c1f5
Degaud, M. (2023) · theses.fr (ABES) · doi:10.70675/017d5580z3800z407fzb0e5z62d50d2f469e
Modeling Chronic Myelomonocytic Leukemia with the Aim of Identifying Novel Therapeutic Targets
Alawieh, D. (2025) · theses.fr (ABES) · doi:10.70675/c7daf13fz397fz4894zbafezd95092b27414
Targeting Epigenetics in Ischemic Stroke: From Mechanisms to Therapeutics
Lan, X., Xie, X., & Deng, C.-Q. (2026) · Current Neuropharmacology · doi:10.2174/011570159x462267260120104242
“Additionally, TET2 can recruit histone deacetylase 2 (HDAC2) to the interleukin 6 (IL-6) promoter region, inhibiting its transcription through histone deacetylation [22].”
Berg, N. K., Kerchberger, V. E., Pershad, Y., Corty, R. W., Bick, A. G., & Ware, L. B. (2026) · medRxiv · doi:10.64898/2026.04.14.26350864
Eldeen, G. N., Sokkar, M. F., Lotfy, R. S., Raslan, H. M., Menyawi, M. E., El-Atrebi, K. A., & Bassyouni, H. T. E. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02223-4
“JMJD3 is a conventionally “repressive” histone modification, and numerous investigations have revealed its role in epigenetic control of genes that promote the inflammatory reactions (Zhang et al. 2019).”
Ren, K., Han, X., Li, E., Wang, P., Bi, H., Cai, W., Aydemir, I., Wai, C. M., Niu, H., Yang, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.01.722102
Self-citationTumor cell-intrinsic TET3 restrains type I interferon signaling and anti-tumor immunity
Liu, L., Zhao, W., Shang, T., Xu, B., Wang, M., Li, X., Min, J., Xu, W., Shen, H., Tan, L., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3239-x
“In addition to catalytic activity-dependent DNA demethylation and transcriptional activation, TET proteins can also repress gene expression by recruiting the SIN3A-HDAC1/2 co-repressor complex (Damal Villivalam et al., 2020; Zhang et al., 2015).”
Self-citationHematopoietic somatic mutations in atherosclerotic cardiovascular disease
Ramos-Neble, B. L., & Fuster, J. J. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120718
TET2 ‐ CHIP : From Mutation to Malady
Jian, H., Sun, M., Xia, X., Su, C., Su, K., Xu, J. L., Yuan, Y., Li, C., Yu, M., & Cheng, X. (2026) · The FASEB Journal · doi:10.1096/fj.202600383r · Cited by 1
“In murine models, TET2 forms a complex with NFKB inhibitor zeta (IκBζ) to recruit histone deacetylase 2 (HDAC2) to the promoter region of the interleukin-6 ( Il6 ) gene, thereby suppressing IL-6 expression and attenuating inflammatory signaling [14].”
Wu, C., Jiang, Y., Xu, Y., Yu, X., Li, D., Wang, Z., Zhang, R., & Sun, M. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122093
Epigenetic regulation of inflammation by dopamine in primary human macrophages
Agarwal, Y., Ramani, M. D., Manikandan, S., Bonar, K. A., Montilla, J., Gaskill, P. J., & Matt, S. M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1779072
“TET2, for example, may recruit HDAC1/2 to speci fi c in fl ammatory gene promotors in a DNA methylation-speci fi c manner (85).”
Research progress on targeted regulatory proteins in the prevention and treatment of atherosclerosis
Wei, Y., Zhang, F., Liao, Y., Zhao, Y., & Guo, J. Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1791961
“Beyond its established role in hematopoietic development, TET2 exerts crucial epigenetic control in maintaining innate immune homeostasis and facilitating in fl ammation resolution by actively repressing pro-in fl ammatory gene transcription (56).”
Byun, S., Lee, C. H., Jang, K., Pak, M., Lee, H.-J., Ryu, S., Jung, I., An, J., & Ko, M. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156685
Yamaguchi, Y., Puri, V., Jania, C. M., Cassidy, O. G., Bolzan, L. R., Mozes, G. D., Brown, E. A., Domènech, S., Miller, C. M., Levi, A. B., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10270484/v1
“Loss of Tet2 can amplify Il6 and Il1b gene expression and promote inflammasome activation[50; 55], contributing to systemic inflammatory disorders, including cardiovascular disease and clonal hematopoiesis–associated pathologies[56; 57; 58; 59].”
Regulation of TET function by PROSER1 in development and hematologic malignancies
Li, X., & Rasmussen, K. D. (2026) · Epigenomics · doi:10.1080/17501911.2026.2698006
Self-citationYousefabadi, E. R., Mostafapour, S., Gholami, D., Yousefabadi, Z. R., Bashandeh, S., Esmaeilzadeh, E., & Khorshid, H. R. K. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12451-0
“Altered expression or activity of TET2 in SLE leads to abnormal DNA methylation patterns, epigenetic instability, and sustained inflammatory signaling, promoting loss of immune tolerance and lymphocyte autoreactivity [22, 23].”
Yousef, E. H., Hawas, S. S., Salama, M. M., Metawee, M. E., Sakr, H. I., Alarfaj, S. J., & Alzokaky, A. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156666
“Studies indicate a deep involvement of IL-6 in the pathogenesis of IBD, with disease severity correlating with IL-6 concentration [9].”
TET2: a critical regulatory hub with broad therapeutic implications across human diseases
Tang, J., Wang, R., Long, L., Ma, W., Han, X., & Fu, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1802805
“Under normal conditions, TET2 recruits HDAC3, which binds to the nuclear factor k B (NF-k B) subunit p65 and persistently suppresses p65 acetylation, reducing the expression of pro-in fl ammatory factors like IL-1 b (13).”
InfluentialWang, H., Yang, Y., Tang, J.-J., Wang, X.-L., Liu, X.-Y., Wang, H., Wang, H., Wang, R., Ma, H.-H., Gu, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76756-1
“Recent breakthroughs in immune epigenetics have underscored histone modi fi cations as pivotal modulators of in fl ammatory gene transcription 12,13 .”
Self-citationLiu, X., Liu, J., Feng, L., Xu, D., Wei, X., & Tong, D. (2026) · Cell Biochemistry and Function · doi:10.1002/cbf.70287
Self-citationWang, J., Fan, X.-Y., & Hu, Z. (2026) · Expert Review of Vaccines · doi:10.1080/14760584.2026.2721724
Streck, E., Harloff, M., Freuer, D., Dintner, S., Dedegkikas, D., Jost, D., Kling, E., Märkl, B., Trepel, M., Hyhlik-Dürr, A., et al. (2026) · JVS Vascular Science · doi:10.1016/j.jvssci.2026.100442
“18,26,28,29 Our finding of numerically elevated IL-6 levels in CHIP carriers with occluded grafts further supports this inflammatory hypothesis, although the sample size precluded formal statistical testing.”
Cheng, J., Tam, E. L., & O'Connell, C. L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1907953
Zhang, Q., Qing, X., Ge, Z., 贺文莲, Liang, G., Zhang, W., Gao, Y., & Ma, J. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168457
Self-citationMu, G., Chong, S., Li, J., Wang, H., Meng, H., Xiang, Q., & Cui, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1892250
Exacerbation of inflammatory bone loss in TET2-driven clonal hematopoiesis
Wang, H., Hu, N., Barovic, M., Pan, B., Cheng, G., Li, X., Li, Y., Lim, J., Zhou, Y., Murray, P. J., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag248
Self-citationШевченко, В. Е., Kushnir, T., Gudkova, M. V., Polynovskiy, A. V., & Arnotskaya, N. E. (2026) · Advances in molecular oncology · doi:10.17650/2313-805x-2026-13-3-80-91
Huang, L., Sheng, J., Chi, L., Xu, Y., & Wang, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1966718
In Vivo CAR T-cell Therapy: Determinants of Response and Durability
Abou‐El‐Enein, M. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-26-0116
Nuclear cGAS inhibits stimulation-induced inflammatory gene transcription via HDAC1
高, 尚., Li, H. P., Yan, S., Hou, S., & Yin, H. H. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2601665123
Ünsal, Ş. E. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1943135
Yamaguchi, Y., Puri, V., Jania, C. M., Cassidy, O. G., Bolzan, L. R., Mozes, G. D., Brown, E. A., Domènech, S., Miller, C., Levi, A. B., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10270484/v2
Epigenetics in development, disease, and therapy: from mechanisms to clinical interventions
Ren, Y., Yang, L., Fei, B., Guo, R., Huang, J., Xu, Z., Wang, R., Zhang, P., Cao, D., Chen, P., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3356-1
Self-citationDu, J., Li, Q., Wang, S.-H., Zhao, Y., & Zhao, K. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1971957
Self-citationGholami, D., Ourang, Z., Saatchi, M., Yousefabadi, E. R., Esmaeilzadeh, E., Akhlaghi, M., Kavosi, H., & Khorshid, H. R. K. (2025) · Reports of Biochemistry and Molecular Biology · doi:10.66224/rbmb.14.2.314
Singh, M., Schümann, M., Elli, L., & Luciani, F. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.10.001
Metadata
- Authors
- Zhang, Q., Zhao, K., Shen, Q., Han, Y., Gu, Y., Li, X., Zhao, D., Liu, Y., Wang, C., Zhang, X., Su, X., Liu, J., Ge, W., Levine, R. L., Li, N., & Cao, X.
- Affiliations
- Second Military Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Cao, Xuetao
- ORCID
- Venue
- Nature
- Published
- 2015-08-19
- Volume
- 525
- Issue
- 7569
- Pages
- 389-393
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4697747
- OpenAlex
- W1171241794
- Cited by
- 807
- References
- 30
- Citations by year
- 2026: 56 · 2025: 77 · 2024: 83 · 2023: 89 · 2022: 93 · 2021: 82 · 2020: 79 · 2019: 85 · 2018: 62 · 2017: 50 · 2016: 43 · 2015: 7
- FWCI
- 23.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA173636, P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- TET2, HDAC2, interleukin-6, inflammation resolution, histone deacetylation, transcriptional repression, 5-hydroxymethylcytosine, IκB, lipopolysaccharide, dendritic cells, macrophages, endotoxic shock, DSS-induced colitis
- MeSH terms
- Interleukin-6 Inhibitors, Acetylation, Animals, Chromatin, Colitis, Dendritic Cells, DNA-Binding Proteins, Female, Histones, Humans, Inflammation, Macrophages, Male, Mice, Inbred C57BL, Promoter Regions, Genetic, Proto-Oncogene Proteins, Transcription, Genetic, Down-Regulation, Interleukin-6, DNA Methylation, I-kappa B Proteins, Epigenesis, Genetic, Dioxygenases, Mice, Histone Deacetylase 2, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.